The short answer
Bitter melon has not been shown to cause added hypoglycemia with canagliflozin. The inspected capsule trial did not clearly improve major glucose measures and did not verify this drug combination.
What this answer covers
Momordica charantia capsules versus food, juice, seed and other extracts.
- Supplement or preparation
- Momordica charantia
- Medication ingredient
- canagliflozin
The controlled result was not clearly positive
A small capsule study on standard diabetes therapy found no significant improvement in HbA1c or fasting glucose. Its abstract does not establish a canagliflozin subgroup.
The whole regimen determines risk
Canagliflozin lowers glucose through urinary glucose loss. Its label particularly flags hypoglycemia with insulin or insulin secretagogues; that warning cannot supply an exact bitter-melon risk rate.
Preparation and endpoint limits remain
A null efficacy result does not prove every extract safe. Lower average glucose also differs from a documented dangerous low.
Review changes with the diabetes team
Discuss the actual supplement and report unusual glucose readings. Follow the prescribed monitoring plan, especially if insulin or a sulfonylurea is also used; do not change medicines yourself.
Evidence and practical considerations
Side effects & toxicity
No verified exact-pair clinical hypoglycemia evidence; capsule null findings and drug/regimen mechanism retained.
- Exact scope
- Momordica charantia capsules versus food, juice, seed and other extracts. with Oral canagliflozin RxCUI1373458 IN; agent-specific renal and metabolic mechanisms.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary interval, class-only metabolism assumption or unmeasured pair-event rate.
Factors that may matter: Preparation; Dose; Kidney function; Volume status; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral canagliflozin
SGLT2 inhibition increases urinary glucose. Volume contraction can cause hypotension or acute kidney injury, with risk modifiers. UGT inducers may lower drug exposure and effectiveness. Insulin/secretagogue co-use increases hypoglycemia risk.
How this applies: Exact single-ingredient canagliflozin, not all SGLT2 agents or combination products.
Warnings do not establish every botanical interaction or routine sodium supplementation. Renal function and whole regimen matter.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40adults with type2diabetes.
No significant improvement in HbA1c or fasting glucose with bitter-melon capsules versus placebo on standard therapy.
How this applies: Indirect for exact canagliflozin; source exposure and clinical endpoint retained.
Small capsule trial; no verified canagliflozin subgroup or clinical hypoglycemia rate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact canagliflozin article separating volume effects, metabolic exposure and intrinsic supplement risks. | |
| Research summary published |
Article revision: 263042af7a094de6
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.